iRhythm Technologies Announces First Quarter 2024 Financial Results

Rhea-AI Summary

iRhythm Technologies, a digital healthcare company, reported first quarter 2024 financial results with revenue of $131.9 million, an 18.4% increase from last year. Gross margin was 66.3% with cash reserves of $569.1 million. They increased their fiscal year 2024 revenue guidance to $578-$588 million. Operational highlights included over half a million registrations and collaborations to drive efficiencies. The CEO highlighted strong revenue growth, increased traction in primary care, and the potential of EKG data for clinical insights.

Positive

• Revenue increased by 18.4% to $131.9 million in the first quarter of 2024 compared to the same period last year, driven by demand for Zio services.

• Gross profit rose by 15.6% to $87.5 million in the first quarter of 2024, primarily due to higher volume of Zio services provided.

• Unrestricted cash, cash equivalents, and marketable securities stood at $569.1 million as of March 31, 2024.

• iRhythm raised their fiscal year 2024 revenue guidance to a range of $578 million to $588 million, projecting a 17% to 19% growth compared to the prior year.

Negative

• Gross margin declined by 160 basis points to 66.3% in the first quarter of 2024 compared to the same period in 2023.

• Operating expenses increased to $125.7 million in the first quarter of 2024, impacting the net loss which was $45.7 million for the quarter.

• Adjusted net loss for the first quarter of 2024 was $38.1 million, or a diluted loss of $1.23 per share, compared to $33.4 million in the same period in 2023.

Financial Analyst

iRhythm Technologies, Inc has reported a substantial 18.4% year-over-year revenue growth in its Q1 2024 financial results, which indicates a robust demand for its Zio services. This uptick in revenue is a positive signal to investors looking for growth in the digital healthcare space. However, it's important to note that while revenue has increased, the company's gross margin has slightly declined by 160 basis points from the previous year, sitting at 66.3%. This margin contraction is attributed to higher costs associated with the commercial launch of their Zio monitor and the scaling of their clinical cardiac technicians. On the balance sheet, a significant cash reserve of $569.1 million provides the company with a cushion for strategic initiatives but also raises the question of whether that capital is being effectively deployed, given the reported net loss of $45.7 million. The updated revenue guidance for 2024 shows confidence in sustained growth, but investors should be wary of the increased operating expenses, which have risen notably from 2023. The provided data suggests a need for more efficient cost management to improve profitability in the long term.

Healthcare Industry Analyst

From a healthcare industry perspective, the operational highlights of iRhythm Technologies suggest a strategic push towards leveraging technology and data analytics to enhance patient care and workflow efficiency for clinicians through EMR integration. The collaboration with Epic's Aura platform is particularly noteworthy as it aims to streamline operations, which could be a critical factor in driving further adoption of Zio services within large care networks. The heart failure prediction algorithm and upcoming data presentation at the Heart Rhythm Society signal ongoing investments in R&D to support EKG as a vital sign for clinical insights. These initiatives are aligned with industry trends towards personalized and predictive healthcare, which may increase the company's market relevance. Investors with an interest in the convergence of technology and healthcare may find these developments promising, although it's essential to balance this against the reported net losses and the challenge of translating these operational efforts into improved financials.

SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2024.

First Quarter 2024 Financial Highlights

• Revenue of $131.9 million, a 18.4% increase compared to first quarter 2023
• Gross margin of 66.3%, a 160-basis point decline compared to first quarter 2023
• Unrestricted cash, cash equivalents and marketable securities of $569.1 million as of March 31, 2024
• Increased fiscal year 2024 revenue guidance to a range of $578 million to $588 million

Recent Operational Highlights

• Over half a million registrations during the first quarter driven by continued growth from primary care prescribers, further penetration within existing accounts, and expansion into near-record new account openings for Zio long-term continuous monitoring services
• Announced collaboration with Epic’s Aura platform to drive efficiencies through EMR integration and enable streamlined access to Zio services through improved operational efficiency for clinicians
• Presented heart failure prediction algorithm data at ACC in April, demonstrative of the scientific evidence our teams and academic partners are generating in support of EKG as a critical vital sign for predictive clinical insights
• Upcoming data presentation at the Heart Rhythm Society (HRS) in Boston, MA, from May 16 - 19, 2024

"During the first quarter of 2024, we were very pleased with the continued momentum in our core markets that enabled record unit volumes as well as strong new account openings," said Quentin Blackford, president and chief executive officer of iRhythm. "First quarter revenue growth of 18.4% year-over-year was driven by sustained growth in our existing accounts but also significant contribution from accounts opened within the past twelve months. We have been very encouraged with the growing traction within the primary care channel, highlighting Zio's value proposition as a workflow efficiency tool to expand ambulatory cardiac monitoring capacity within large care networks. When combined with progress that we are making with electronic health integration and emerging clinical evidence on the potential for EKG data to provide future clinical insights, we could not be more excited about our positioning to create significant value for patients, clinicians, healthcare systems, and stakeholders."

First Quarter Financial Results
Revenue for the first quarter of 2024 was $131.9 million, up 18.4% from $111.4 million during the same period in 2023. The increase was driven by growth in demand for Zio services.

Gross profit for the first quarter of 2024 was $87.5 million, up 15.6% from $75.7 million during the same period in 2023, while gross margin was 66.3%, down from 67.9% during the same period in 2023. The increase in gross profit was primarily due to increased volume of Zio services provided due to higher demand. The decrease in gross margin was primarily due to accelerated recognition of the cost of our legacy Zio XT components associated with our ongoing Zio monitor commercial launch as well as costs related to scaling and training newly onboarded clinical cardiac technicians at our San Francisco IDTF center of excellence.

Operating expenses for the first quarter of 2024 were $125.7 million, compared to $115.2 million for the same period in 2023. Adjusted operating expenses for the first quarter of 2024 were $125.7 million, compared to $109.5 million during the same period in 2023. This increase in adjusted operating expenses resulted primarily from increased headcount-related and third-party costs to support growth in operations and the further development, enhancement, and functionality of our current and future product offerings.

Net loss for the first quarter of 2024 was $45.7 million, or a diluted loss of $1.47 per share, compared with net loss of $39.1 million, or a diluted loss of $1.29 per share, for the same period in 2023. Adjusted net loss for the first quarter of 2024 was $38.1 million, or a diluted loss of $1.23 per share, compared with an adjusted net loss of $33.4 million, or a diluted loss of $1.10 per share, for the same period in 2023.

Unrestricted cash, cash equivalents, and marketable securities were $569.1 million as of March 31, 2024.

2024 Annual Guidance
iRhythm projects revenue for the full year 2024 to grow approximately 17% to 19% compared to prior year results, ranging from approximately $578 million to $588 million. Gross margin for the full year 2024 is expected to range from 68% to 69% and adjusted EBITDA margin for the full year 2024 is expected to range from approximately 3% to 4% of revenues.

Webcast and Conference Call Information
iRhythm’s management team will host a conference call today beginning at 1:30 p.m. PT/4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.

About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Use of Non-GAAP Financial Measures
We refer to certain financial measures that are not recognized under U.S. generally accepted accounting principles (GAAP) in this press release, including adjusted EBITDA, adjusted net loss, adjusted net loss per share and adjusted operating expenses. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. See the schedules attached to this press release for additional information and reconciliations of such non-GAAP financial measures. We have not reconciled our adjusted operating expenses and adjusted EBITDA estimates for full year 2024 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, a reconciliation of adjusted operating expenses and adjusted EBITDA estimates is not available without unreasonable effort.

Adjusted EBITDA excludes non-cash operating charges for stock-based compensation, depreciation and amortization as well as non-operating items such as interest income, interest expense, impairment and restructuring charges, loss on extinguishment of debt, and business transformation costs.

We exclude the following items from non-GAAP financial measures for adjusted net loss, adjusted net loss per share and adjusted operating expenses:

• impairment and restructuring charges,
• loss on extinguishment of debt, and
• business transformation costs to scale the organization.
  

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding financial guidance, market opportunity, ability to penetrate the market, anticipated productivity improvements and expectations for growth. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission, including those on the Form 10-Q expected to be filed on or about May 2, 2024. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.

Investor Relations Contact
Stephanie Zhadkevich
(919) 452-5430
investors@irhythmtech.com

iRhythm Media Contact
Saige Smith
(262) 289-7065
irhythm@highwirepr.com

IRHYTHM TECHNOLOGIES, INC. Condensed Consolidated Balance Sheets (unaudited) (In thousands, except par value)
	March 31, 2024				December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$	520,421			$	36,173
Marketable securities		48,671				97,591
Accounts receivable, net		89,712				61,484
Inventory		14,873				13,973
Prepaid expenses and other current assets		13,778				21,591
Total current assets		687,455				230,812
Property and equipment, net		112,274				104,114
Operating lease right-of-use assets		48,073				49,317
Restricted cash, long-term		8,358				—
Goodwill		862				862
Other assets		52,733				48,039
Total assets	$	909,755			$	433,144
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	8,440			$	5,543
Accrued liabilities		70,044				83,362
Deferred revenue		3,068				3,306
Operating lease liabilities, current portion		15,289				15,159
Total current liabilities		96,841				107,370
Long-term senior convertible notes		644,076				—
Debt, noncurrent portion		—				34,950
Other noncurrent liabilities		908				1,012
Operating lease liabilities, noncurrent portion		77,640				79,715
Total liabilities		819,465				223,047
Stockholders’ equity:
Preferred stock, $0.001 par value – 5,000 shares authorized; none issued and outstanding at March 31, 2024 and December 31, 2023		—				—
Common stock, $0.001 par value – 100,000 shares authorized; 31,326 shares issued and 31,097 shares outstanding at March 31, 2024, respectively; and 30,954 shares issued and outstanding at December 31, 2023		31				31
Additional paid-in capital		806,621				855,784
Accumulated other comprehensive loss		(89	)			(112	)
Accumulated deficit		(691,273	)			(645,606	)
Treasury stock, at cost; 229 and 0 shares at March 31, 2024 and December 31, 2023, respectively		(25,000	)			—
Total stockholders’ equity		90,290				210,097
Total liabilities and stockholders’ equity	$	909,755			$	433,144

IRHYTHM TECHNOLOGIES, INC. Condensed Consolidated Statements of Operations (unaudited) (In thousands, except per share data)
		Three Months Ended March 31,
			2024				2023
Revenue, net		$	131,929			$	111,436
Cost of revenue			44,413				35,755
Gross profit			87,516				75,681
Operating expenses:
Research and development			16,994				14,842
Selling, general and administrative			108,660				100,343
Total operating expenses			125,654				115,185
Loss from operations			(38,138	)			(39,504	)
Interest expense			(2,860	)			(950	)
Interest and other income, net			2,952				1,432
Loss on extinguishment of debt			(7,589	)			—
Loss before income taxes			(45,635	)			(39,022	)
Income tax provision			32				87
Net loss		$	(45,667	)		$	(39,109	)
Net loss per common share, basic and diluted		$	(1.47	)		$	(1.29	)
Weighted-average shares, basic and diluted			31,033				30,297

IRHYTHM TECHNOLOGIES, INC. Reconciliation of GAAP to Non-GAAP Financial Information (unaudited) (in thousands, except per share data)
		Three Months Ended March 31,
			2024				2023
Adjusted EBITDA reconciliation
Net loss		$	(45,667	)		$	(39,109	)
Interest expense			2,860				950
Interest income			(3,057	)			(1,434	)
Income tax provision			32				87
Depreciation and amortization			5,131				3,576
Stock-based compensation			20,991				18,251
Business transformation costs			—				5,686
Loss on extinguishment of debt			7,589				—
Adjusted EBITDA		$	(12,121	)		$	(11,993	)

		Three Months Ended March 31,
			2024				2023
Adjusted net loss reconciliation
Net loss, as reported		$	(45,667	)		$	(39,109	)
Business transformation costs			—				5,686
Loss on extinguishment of debt			7,589				—
Adjusted net loss		$	(38,078	)		$	(33,423	)
Adjusted net loss per share reconciliation
Net loss per share, as reported		$	(1.47	)		$	(1.29	)
Business transformation costs per share			—				0.19
Loss on extinguishment of debt			0.24				—
Adjusted net loss per share		$	(1.23	)		$	(1.10	)
Weighted-average shares, basic and diluted			31,033				30,297
Adjusted operating expense reconciliation
Operating expense, as reported		$	125,654			$	115,185
Business transformation costs			—				(5,686	)
Adjusted operating expense		$	125,654			$	109,499

FAQ

What was iRhythm Technologies' revenue for the first quarter of 2024?

iRhythm reported revenue of $131.9 million for the first quarter of 2024, a 18.4% increase compared to the same period in 2023.

What were the operational highlights of iRhythm in the first quarter of 2024?

Operational highlights for iRhythm in the first quarter of 2024 included over half a million registrations, collaborations with Epic's Aura platform, and heart failure prediction algorithm data presentation at ACC.

What is iRhythm's fiscal year 2024 revenue guidance?

iRhythm expects revenue for the full year 2024 to be in the range of $578 million to $588 million, projecting a 17% to 19% growth compared to the previous year.